Men facing aggressive prostate cancer surgery now have compelling evidence for a treatment approach that could dramatically reduce their chances of disease recurrence. The addition of hormone-blocking therapy before and after surgical removal appears to offer substantial protection against cancer returning. The PROTEUS trial evaluated apalutamide, an androgen receptor inhibitor, in 1,504 men with high-risk localized prostate cancer undergoing radical prostatectomy. Patients received either the drug or placebo for 12 weeks before surgery and 24 weeks afterward. Those taking apalutamide showed a 42% reduction in metastasis-free survival events compared to placebo, with the drug group achieving 93.5% metastasis-free survival at two years versus 89.1% for placebo. The treatment also significantly improved biochemical recurrence-free survival and pathological complete response rates. This perioperative approach represents a notable evolution in prostate cancer management, extending hormone therapy beyond its traditional role in advanced disease into the curative setting. The strategy builds on decades of research showing androgen deprivation can shrink tumors and eliminate microscopic cancer cells that standard surgery might miss. However, the relatively short follow-up period means long-term survival benefits remain uncertain. The trial's focus on high-risk patients also leaves questions about broader applicability. While promising, this intervention adds complexity and potential side effects to an already challenging treatment journey, requiring careful patient selection and counseling about the trade-offs between immediate intervention and watchful monitoring.